Trial of Preoperative Hepatic and Regional Arterial Chemotherapy (PHRAC) to Prevent Postoperative Liver Metastasis of Colorectal Cancer (PHRAC)
A Prospective,Multi-Center,Randomized Control Trial of Preoperative Hepatic and Regional Arterial Chemotherapy(PHRAC) Using Oxaliplatin, Fluorodeoxyuridine(FUDR) and Mitomycin C(MMC) to Prevent Postoperative Liver Metastasis of Colorectal Cancer
Sponsor: First Affiliated Hospital of Zhejiang University
Listed as NCT00643877, this PHASE3 trial focuses on Colorectal Neoplasms and remains ongoing. Sponsored by First Affiliated Hospital of Zhejiang University, it has been updated 7 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Jan 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2024 — Jan 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
-
Oct 2018 — Jan 2021 [monthly]
Unknown Status PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Oct 2018 [monthly]
Unknown Status PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE3
First recorded
Dec 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- First Affiliated Hospital of Zhejiang University
- Fudan University
- Jiangyin People's Hospital
- Liaoning Cancer Hospital & Institute
- Ruijin Hospital
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
For direct contact, visit the study record on ClinicalTrials.gov .